Showing results (1141-1150 of 1,832) with videos related to

Sort By:
Pageof 184
Signal Transduction and Targeted Therapy|April 17, 2020
Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathwayLisha Du, Zikang Xing, Bangbao Tao, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
C3G contributes to platelet activation and aggregation by regulating major signaling pathwaysSara Gutiérrez-Herrero, Cristina Fernández-Infante, Luis Hernández-Cano, et al.
Signal Transduction and Targeted Therapy|September 2, 2021
Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trialJun Liu, Dan-Dan Li, Wei Dong, et al.
Signal Transduction and Targeted Therapy|September 2, 2021
Pro-inflammatory microenvironment and systemic accumulation of CXCR3+ cell exacerbate lung pathology of old rhesus macaques infected with SARS-CoV-2Hong-Yi Zheng, Xiao-Yan He, Wei Li, et al.
Signal Transduction and Targeted Therapy|September 1, 2021
A novel missense variant in ACAA1 contributes to early-onset Alzheimer's disease, impairs lysosomal function, and facilitates amyloid-β pathology and cognitive declineRongcan Luo, Yu Fan, Jing Yang, et al.
Signal Transduction and Targeted Therapy|August 2, 2022
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasisFubing Li, Huichun Liang, Hua You, et al.
Signal Transduction and Targeted Therapy|September 8, 2025
Epidemiological and phylogenetic characteristics of human metapneumovirus in Beijing, China, 2014-2024Aihua Li, Cheng Gong, Liang Wang, et al.
Signal Transduction and Targeted Therapy|September 10, 2025
Astrocytic monoamine oxidase B (MAOB)-gamma-aminobutyric acid (GABA) axis as a molecular brake on repair following spinal cord injuryHye Yeong Lee, Jung Moo Lee, Hye-Lan Lee, et al.
Signal Transduction and Targeted Therapy|August 3, 2025
Mitochondrial metabolism and cancer therapeutic innovationHongxiang Du, Tianhan Xu, Sihui Yu, et al.
Signal Transduction and Targeted Therapy|August 20, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 studyGuoming Shi, Xiaoyong Huang, Liang Ma, et al.
Pageof 184